CHCWM – Cancer & Hematology Centers of West Michigan

TPST-1495  (Tempest Therapeutics, Inc)

Description:  A Phase 1a/1b Open-label, Dose-Escalation and Expansion Study of TPST-1495 as a Single Agent and in Combination with Pembrolizumab in Subjects with Solid Tumors

Mechanism of Action:  EP2/EP4 antagonist (blocks PGE2 mediated immune suppression in the tumor microenvironment)

Target Patient Population:  Uterine, Head and Neck, CRC and tumors with PIK3A  in combination with Pembrolizumab

Study Design:  Drug is given orally BID.